Results 21 to 30 of about 3,975 (165)

High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients [PDF]

, 2022
Integrase inhibitors (INIs) are an important class of drugs for treating HIV-2 infection, given the limited number of drugs active against this virus. While the clinical efficacy of raltegravir and dolutegravir is well established, the clinical efficacy ...
Ana Rita Diniz, Teresa M. V. D. Pinho e Melo, Melo, Teresa M. V. D. Pinho E, Francisco Martin, Barahona, Isabel, Moranguinho, Inês, Fátima Gonçalves, Caixas, Umbelina, Alves, Nuno, Inês Moranguinho, Pinho e Melo, Teresa M. V. D., Inês Figueiredo, Gonçalves, Paloma, Gonçalves, Fátima, Paloma Gonçalves, Alves, Américo J.S., Gonçalves, Maria Fátima, Perpétua Gomes, Nuno Alves, Borrego, Pedro, Nuno Taveira, Martin, Francisco, Inês Bártolo, Diniz, Ana Rita, Américo J. S. Alves, Pinho e Melo, Teresa M.V.D., Pedro Borrego, Alves, Américo, Moura, Ines, Isabel Barahona, Figueiredo, Inês, Bártolo, Inês, Gomes, Perpétua, Pinto, Inês V., Umbelina Caixas, Vaz-Pinto, Inês, Inês V. Pinto, Alves, Américo J. S., Taveira, Nuno   +38 more
core   +1 more source

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports

Drugs in Context, 2023
Background: Metabolic effects of integrase strand transfer inhibitors (INSTIs) have been reported. The FDA Adverse Event Reporting System (FAERS) is a publicly available database that captures spontaneously reported adverse events.
Milena M Murray, Lara Fakhouri, Spencer E Harpe   +2 more
doaj   +1 more source

Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment

, 2021
International audienceObjectives: The penetration of antiretroviral drugs into deep compartments, such as the CNS, is a crucial component of strategies towards an HIV cure.
Gasnault, Jacques, Gelé, Thibaut, Chéret, Antoine, Barrail-Tran, Aurélie, Goujard, Cécile D.Sign©cile, Taburet, Anne Marie, Pallier, Coralie, Gouget, Hélène, Castro Gordon, Alicia, Becker, Pierre Hadrien, Catalan, Pilartxo, Nkam, Lionelle, Furlan, Valérie   +12 more
core   +1 more source

Are new antiretroviral treatments increasing the risks of clinical obesity?

Journal of Virus Eradication, 2019
There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant.
Andrew Hill, Laura Waters, Anton Pozniak
doaj   +1 more source

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Antiviral Therapy, 2023
Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in
Charlotte-Paige Rolle MD, MPH, Jamie Castano, Vu Nguyen MS, Kiran Patel, Federico Hinestrosa MD, Edwin DeJesus MD   +5 more
doaj   +1 more source

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice [PDF]

, 2022
We evaluated virological response and resistance profile in virologically suppressed individuals switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in real ...
Gennari, W, Borghi, V, Forbici, F, Andreoni, M, Gagliardini, R, Latini, A, Cicalini, S, Armenia, D, Berno, G, Lanini, S, Sarmati, L, Mussini, C, Santoro, M M, Bertoli, A, Santoro, M, Antinori, A, Perno, C F, Malagnino, V, Teti, E, Buonomini, A, Ceccherini-Silberstein, F   +20 more
core   +1 more source

Baseline characteristics of 539 patients on Emtricitabine/Tenofovir Alafenamide/Bictegravir, enrolled in the SCOLTA cohort.

, 2023
Baseline characteristics of 539 patients on Emtricitabine/Tenofovir Alafenamide/Bictegravir, enrolled in the SCOLTA cohort.
Paolo Bonfanti (383173), Eleonora Sarchi (622896), Antonio Di Biagio (316138), Goffredo Angioni (9729449), Giuseppe Vittorio De Socio (7513244), Giovanni Cenderello (648635), Paolo Maggi (4162249), Stefania Piconi (7513250), Benedetto Maurizio Celesia (7513253), Letizia Attala (16806786), Olivia Bargiacchi (16806789), Barbara Menzaghi (316146), Nicola Squillace (691608), Alessandra Bandera (340441), Lucia Taramasso (344095), Katia Falasca (4162252), Laura Valsecchi (13852802), Filomena Simeone (16806783), Elena Ricci (316160), Giancarlo Orofino (485009), Giovanni Francesco Pellicanò (4162270), Antonio Cascio (378202)   +21 more
core   +1 more source

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)

Infectious Disease Reports, 2023
Background: Bictegravir (BIC), a recently introduced integrase inhibitor, is available in a single tablet regimen with tenofovir alafenamide (TAF) and emtricitabine (FTC) (BIC-STR).
Anna Gidari, Sara Benedetti, Sara Tordi, Anastasia Zoffoli, Debora Altobelli, Elisabetta Schiaroli, Giuseppe Vittorio De Socio, Daniela Francisci   +7 more
doaj   +1 more source

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort

Viruses, 2023
Background: Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH).
Alessandro Lazzaro, Diana Bianchini, Elio Gentilini Cacciola, Ivano Mezzaroma, Mario Falciano, Carolina Andreoni, Caterina Fimiani, Letizia Santinelli, Luca Maddaloni, Ginevra Bugani, Giancarlo Ceccarelli, Claudio Maria Mastroianni, Gabriella d’Ettorre   +12 more
doaj   +1 more source

Bictegravir-Induced Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Acute Human Immunodeficiency Virus

, 2023
Although drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with antiretrovirals, there are no published reports of bictegravir-induced DRESS.
DiLorenzo, Madeline A., Chen, Jason N., Mgbako, Ofole, Bawany, Fatima, Taunk, Pulkit, Tran, Duy C., Pomeranz, Miriam Keltz, Meehan, Shane A., Medrano, Nicola   +8 more
core   +1 more source